For a large percentage of new and costly cancer drugs, often approved for use in Europe based on surrogate endpoints, data in the years after approval failed to show extended overall survival or improved quality of life, according to a study in the British Medical Journal. The FDA is also increasingly relying on endpoints other than overall survival and quality of life changes, Dr. Vinay Prasad wrote in an accompanying editorial.
Majority of new cancer drugs don't extend, improve life, study finds
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.